X4 Pharmaceuticals (XFOR) Misses Q3 EPS by 4c; Cash and Cash Equivalents of $77.7M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
X4 Pharmaceuticals to Have Strong Presence at ASH 2021 with Seven Accepted Abstracts Highlighting New Clinical and Scientific Data; Company Reports Third Quarter Financial Results
November 4, 2021 9:01 AM EDTData continue to support mavorixafors potential to benefit patients with WHIM syndrome, chronic neutropenia, and Waldenströms macroglobulinemia
Discovery of new prevalent WHIM variant further validates the companys U.S. WHIM prevalence projections
Company to host an Investor Day on December 16 with key opinion leaders leading discussions on four poster presentations and additional clinical and scientific data
Conference call today at 9:05 a.m. ET
BOSTON, Nov. 04,... More
